Clinical experience with the use of infliximab in 44 patients with Crohn's disease

Abstract

Aim - To evaluate the efficacy of infliximab in the treatment of patients with active Crohn's disease or with fistulas. Methods - Forty four patients with Crohn's disease, resistant to conventional therapies, were treated with 5 mg/kg endovenous infliximab infusions. Results - Thirty of them (68.2%) improved, with important reduction on disease activity levels, measured by the CDAI (Crohn's Disease Activity Index). Eight (57.1%) of 14 patients with fistulas also showed good results, with closure or important reduction in their flow. The drug was well tolerated in all cases. Conclusion - The use of infliximab in these cases seems to be a good therapeutic option, with low rates of side effects.